Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moxonidine for fatty liver disease
ACTRN12617000948392Phase 4Not yet recruiting
- Sponsor
- Baker Heart and Diabetes Institute
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in metabolic dysfunction-associated steatotic liver disease (MASLD) comparing Moxonidine with Placebo (2 arms). Primary endpoints: Change in MRI-assessed liver fat quantification and Change in HOMA index. Planned start Jul 2017; status: not yet recruiting.
02
Drugs
moxonidine
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on ACTRN12617000948392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000948392.